Ranbaxy Laboratories

Ranbaxy Laboratories News

Delhi High Court ruling: Partial sale of assets in Daiichi case

Justice Jayant Nath also directed the debtors to fully cooperate with the chartered accountant, who was appointed a local commissioner in the matter, to sell these shares at the stock exchange.

2008 Ranbaxy stake sale: Singh brothers asked to pay Rs 2,562 cr to Daiichi Sankyo

Ex-promoters ‘concealed and misrepresented information’: Singapore tribunal.

Advertising

Germany bans drug made at Ranbaxy’s Dewas plant

During the inspection, the regulator found deficiencies related to operation of drug manufacturing rooms and procedures.

Ranbaxy Laboratories to pay $40 mn to settle pricing litigation case in US

Ranbaxy settlement comes after it pleaded guilty last year to felony charges relating to drug safety.

India Inc back to M&A deals, driven by positive sentiment

Merger and acquisition activity involving Indian companies has seen a jump buoyed by the improvement in GDP growth numbers and projections of better prospects for the economy going forward. The first nine months of calendar 2014 saw a 16.5 per cent rise in the merger and acquisition (M&A) deals at $26.1 billion over that in 2013. […]

Ranbaxy Laboratories quarterly net loss narrows to Rs 185.92 cr

Consolidated net sales of Ranbaxy Laboratories stood at Rs 2,372.24 crore.

Advertising

Andhra HC vacates status quo order on $4 bn Sun Pharma-Ranbaxy merger

SC earlier observed that Andhra HC has no territorial jurisdiction over Sun Pharma-Ranbaxy merger process.

SC finds fault in stay on Ranbaxy merger deal

The bench observed that the filing of writ petitions in the Andhra High Court may signify “forum shopping” in view of the fact that petitions on merger were already pending before high courts of Gujarat and Punjab.

Daiichi plea in HC to vacate stay on Ranbaxy merger

The petitioners alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6.

Ranbaxy posts loss after write-offs on US bans

The Japan’s Daiichi Sankyo-owned firm made a provision of Rs 62.95 crore for inventory write-off and other costs.

Advertising